– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces – Expected ...
AIM ImmunoTech Inc. announced its participation in the Virtual Investor “Top 5 for ‘25” On-Demand Conference, where CEO Thomas K. Equels highlighted five key areas deserving investor attention in 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results